Zydus Lifesciences surges on getting USFDA`s final approval for Diltiazem Hydrochloride Tablets
Zydus Lifesciences is currently trading at Rs 953.70, up by 18.20 points or 1.95% from its previous closing of Rs 935.50 on the BSE.
The scrip opened at Rs 936.55 and has touched a high and low of Rs 955.00 and Rs 934.60 respectively. So far 11860 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1323.90 on 09-Aug-2024 and a 52-week low of Rs 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs 964.55 and Rs 917.50 respectively. The current market cap of the company is Rs 95506.70 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.26% and 6.74% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg (USRLD: Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg). Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. It belongs to a class of drugs called calcium-channel blockers. Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle.
Diltiazem Hydrochloride Tablets will be produced at Zydus Lifesciences, Baddi, Himachal Pradesh. Diltiazem Hydrochloride Tablets had annual sales of $13.9 million in the United States (IQVIA MAT June 2025). The group now has 423 approvals and has so far filed around 483 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
